Datapoint: Actemra Scores Systemic Sclerosis Nod

The FDA last week cleared Genentech’s Actemra for the treatment of systemic sclerosis, a rare autoimmune disease occurring in patients with interstitial lung disease. The drug is the first biologic approved for this condition, and will be Actemra’s sixth FDA-granted indication overall. For the treatment of rheumatoid arthritis, Actemra currently holds preferred status for 21% of all covered lives under the pharmacy benefit, with utilization management restrictions applied in most cases. The biologic is classified as a specialty drug for 14% of covered lives.

SOURCE: MMIT Analytics, as of 3/8/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 1

Datapoint: United to Join Massachusetts Duals Demo

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 30

Datapoint: Oscar, Emory to Offer New Health Plan in Georgia

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 24

Datapoint: Keytruda Scores Major Kidney Cancer Nod

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today